Muctarr Sesay

home / authors / muctarr-sesay

Muctarr Sesay, PhD, is chief scientific officer and vice-president of Bioconjugation at Goodwin Biotechnology.

Articles

Optimizing a Unique Cancer Vaccine for Intradermal Delivery

Optimizing a Unique Cancer Vaccine for Intradermal Delivery

Muctarr Sesay;Mark Tomai;Steven Fuller;John Price;Dave Cunningham

September 15th 2017

Using a hollow microstructured transdermal system to deliver vaccine directly to the dermis.

Monoclonal Antibody Conjugation via Chemical Modification

Monoclonal Antibody Conjugation via Chemical Modification

December 1st 2003

Bioconjugation chemistry is the joining of biomolecules to other biomolecules, small molecules, and polymers by chemical or biological means.

Latest Updated Articles

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com

Published: September 11th 2024 | Updated: September 18th 2024

CPHI Pharma Award Finalists Announced for 2024

Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com

Published: March 27th 2024 | Updated: June 28th 2024

AbbVie Acquires Landos Biopharma and Gets Full FDA Nod for ADC Product

Published: December 9th 2024 | Updated: December 26th 2024

Recap Key Industry Trends for Viral Clearance and NGS

Shining Pro - Stock.Adobe.com

Published: December 7th 2024 | Updated: December 26th 2024

Enhancing Quality Through Training

Published: July 20th 2020 | Updated: December 26th 2024

Contact BioPharm International Editors

Published: July 19th 2020 | Updated: December 26th 2024

Editorial Information: BioPharm International Submission Guidelines and Editorial Calendars

Editorial Information

Do Not Sell My Personal Information

Terms and Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2024 MJH Life Sciences

All rights reserved.